Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 652

1.

The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females.

Chen Y, Moutal A, Navratilova E, Kopruszinski C, Yue X, Ikegami M, Chow M, Kanazawa I, Bellampalli SS, Xie J, Patwardhan A, Rice K, Fields H, Akopian A, Neugebauer V, Dodick D, Khanna R, Porreca F.

Sci Transl Med. 2020 Feb 5;12(529). pii: eaay7550. doi: 10.1126/scitranslmed.aay7550. Erratum in: Sci Transl Med. 2020 Mar 4;12(533):.

PMID:
32024801
2.

Modulators of Fam210a and Roles of Fam210a in the Function of Myoblasts.

Tanaka KI, Kanazawa I, Richards JB, Goltzman D, Sugimoto T.

Calcif Tissue Int. 2020 Jan 24. doi: 10.1007/s00223-020-00661-y. [Epub ahead of print]

PMID:
31980842
3.

Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis via NADPH Oxidase-Interleukin 1β and 6 Pathway in Osteocyte-like Cells.

Notsu M, Kanazawa I, Takeno A, Tanaka KI, Sugimoto T.

Calcif Tissue Int. 2019 Oct;105(4):446-457. doi: 10.1007/s00223-019-00580-7. Epub 2019 Jun 27.

PMID:
31250042
4.

Phloretin Suppresses Bone Morphogenetic Protein-2-Induced Osteoblastogenesis and Mineralization via Inhibition of Phosphatidylinositol 3-kinases/Akt Pathway.

Takeno A, Kanazawa I, Tanaka KI, Notsu M, Sugimoto T.

Int J Mol Sci. 2019 May 20;20(10). pii: E2481. doi: 10.3390/ijms20102481.

5.

Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.

Tanaka S, Yamamoto M, Morita M, Takeno A, Kanazawa I, Yamaguchi T, Yamada S, Inoshita N, Oki Y, Kurosaki M, Sugimoto T.

Endocr J. 2019 Aug 29;66(8):701-708. doi: 10.1507/endocrj.EJ18-0547. Epub 2019 May 25.

6.

Low skeletal muscle mass is associated with the risk of all-cause mortality in patients with type 2 diabetes mellitus.

Miyake H, Kanazawa I, Tanaka KI, Sugimoto T.

Ther Adv Endocrinol Metab. 2019 Apr 22;10:2042018819842971. doi: 10.1177/2042018819842971. eCollection 2019.

7.

Insulin-Like Growth Factor-I Protects Against the Detrimental Effects of Advanced Glycation End Products and High Glucose in Myoblastic C2C12 Cells.

Adachi N, Kanazawa I, Tanaka KI, Takeno A, Notsu M, Tanaka S, Sugimoto T.

Calcif Tissue Int. 2019 Jul;105(1):89-96. doi: 10.1007/s00223-019-00537-w. Epub 2019 Feb 26.

PMID:
30809689
8.

Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.

Takeno A, Yamamoto M, Morita M, Tanaka S, Kanazawa I, Yamauchi M, Kaneko S, Sugimoto T.

BMC Endocr Disord. 2019 Feb 19;19(1):25. doi: 10.1186/s12902-019-0335-x.

9.

A scoring assessment tool for the risk of vertebral fractures in patients with type 2 diabetes mellitus.

Kanazawa I, Tanaka KI, Takeo A, Notsu M, Miyake H, Sugimoto T.

Bone. 2019 May;122:38-44. doi: 10.1016/j.bone.2019.02.003. Epub 2019 Feb 11.

PMID:
30763635
10.

Nerve conduction velocity is negatively associated with intima-media thickness and brachial-ankle pulse wave velocity in men with type 2 diabetes mellitus.

Tanaka S, Kanazawa I, Sugimoto T.

PLoS One. 2018 Dec 20;13(12):e0209503. doi: 10.1371/journal.pone.0209503. eCollection 2018.

11.

Phosphorylated CRMP2 Regulates Spinal Nociceptive Neurotransmission.

Yu J, Moutal A, Dorame A, Bellampalli SS, Chefdeville A, Kanazawa I, Pham NYN, Park KD, Weimer JM, Khanna R.

Mol Neurobiol. 2019 Jul;56(7):5241-5255. doi: 10.1007/s12035-018-1445-6. Epub 2018 Dec 18.

PMID:
30565051
12.

Higher Serum Uric Acid is a Risk Factor of Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes Mellitus.

Tanaka KI, Kanazawa I, Notsu M, Sugimoto T.

Exp Clin Endocrinol Diabetes. 2020 Jan;128(1):66-71. doi: 10.1055/a-0815-4954. Epub 2018 Dec 18.

PMID:
30562825
13.

Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus.

Tanaka KI, Kanazawa I, Notsu M, Sugimoto T.

Exp Clin Endocrinol Diabetes. 2018 Dec 12. doi: 10.1055/a-0805-2197. [Epub ahead of print]

PMID:
30541167
14.

[Secondary osteoporosis. Bone quality deterioration in lifestyle-related disease.]

Kanazawa I.

Clin Calcium. 2018;28(12):1581-1589. doi: CliCa181215811589. Japanese.

PMID:
30487321
15.

Overweight and underweight are risk factors for vertebral fractures in patients with type 2 diabetes mellitus.

Kanazawa I, Notsu M, Takeno A, Tanaka KI, Sugimoto T.

J Bone Miner Metab. 2019 Jul;37(4):703-710. doi: 10.1007/s00774-018-0960-x. Epub 2018 Sep 20.

PMID:
30238431
16.

Osteoporosis and vertebral fracture are associated with deterioration of activities of daily living and quality of life in patients with type 2 diabetes mellitus.

Kanazawa I, Takeno A, Tanaka KI, Yamane Y, Sugimoto T.

J Bone Miner Metab. 2019 May;37(3):503-511. doi: 10.1007/s00774-018-0948-6. Epub 2018 Sep 6.

PMID:
30191456
17.

Albuminuria Increases All-Cause Mortality in Japanese Patients with Type 2 Diabetes Mellitus.

Miyake H, Kanazawa I, Sugimoto T.

J Clin Med. 2018 Aug 23;7(9). pii: E234. doi: 10.3390/jcm7090234.

18.

Osteoblast AMP-activated protein kinase regulates glucose metabolism and bone mass in adult mice.

Kanazawa I, Takeno A, Tanaka KI, Notsu M, Sugimoto T.

Biochem Biophys Res Commun. 2018 Sep 10;503(3):1955-1961. doi: 10.1016/j.bbrc.2018.07.141. Epub 2018 Jul 30.

PMID:
30072101
19.

The Association Between Osteocalcin and Chronic Inflammation in Patients with Type 2 Diabetes Mellitus.

Kanazawa I, Tanaka S, Sugimoto T.

Calcif Tissue Int. 2018 Dec;103(6):599-605. doi: 10.1007/s00223-018-0460-y. Epub 2018 Jul 26.

PMID:
30051143
20.

Assessment using serum insulin-like growth factor-I and bone mineral density is useful for detecting prevalent vertebral fractures in patients with type 2 diabetes mellitus.

Kanazawa I, Notsu M, Miyake H, Tanaka K, Sugimoto T.

Osteoporos Int. 2018 Nov;29(11):2527-2535. doi: 10.1007/s00198-018-4638-y. Epub 2018 Jul 20.

PMID:
30030585
21.

Prehypertension increases the risk of atherosclerosis in drug-naïve Japanese patients with type 2 diabetes mellitus.

Kanazawa I, Sugimoto T.

PLoS One. 2018 Jul 20;13(7):e0201055. doi: 10.1371/journal.pone.0201055. eCollection 2018.

22.

Visceral fat accumulation is associated with increased plasma sphingosine-1-phosphate levels in type 2 diabetes mellitus.

Tanaka S, Kanazawa I, Sugimoto T.

Diabetes Res Clin Pract. 2018 Sep;143:146-150. doi: 10.1016/j.diabres.2018.07.003. Epub 2018 Jul 11.

PMID:
30006309
23.

[Body weight and bone/calcium metabolism. Bone and calcium metabolism in metabolic syndrome.]

Kanazawa I, Sugimoto T.

Clin Calcium. 2018;28(7):897-905. doi: CliCa1807897905. Japanese.

PMID:
29950541
24.

Phloretin Promotes Adipogenesis via Mitogen-Activated Protein Kinase Pathways in Mouse Marrow Stromal ST2 Cells.

Takeno A, Kanazawa I, Notsu M, Tanaka KI, Sugimoto T.

Int J Mol Sci. 2018 Jun 14;19(6). pii: E1772. doi: 10.3390/ijms19061772.

25.

Diabetes Mellitus-induced Bone Fragility.

Kanazawa I, Sugimoto T.

Intern Med. 2018 Oct 1;57(19):2773-2785. doi: 10.2169/internalmedicine.0905-18. Epub 2018 May 18.

26.

FAM210A is a novel determinant of bone and muscle structure and strength.

Tanaka KI, Xue Y, Nguyen-Yamamoto L, Morris JA, Kanazawa I, Sugimoto T, Wing SS, Richards JB, Goltzman D.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3759-E3768. doi: 10.1073/pnas.1719089115. Epub 2018 Apr 4.

27.

Inhibition of adenosine monophosphate-activated protein kinase suppresses bone morphogenetic protein-2-induced mineralization of osteoblasts via Smad-independent mechanisms.

Takeno A, Kanazawa I, Notsu M, Tanaka KI, Sugimoto T.

Endocr J. 2018 Mar 28;65(3):291-298. doi: 10.1507/endocrj.EJ17-0229. Epub 2017 Dec 16.

28.

Osteoblast AMP-Activated Protein Kinase Regulates Postnatal Skeletal Development in Male Mice.

Kanazawa I, Takeno A, Tanaka KI, Notsu M, Sugimoto T.

Endocrinology. 2018 Feb 1;159(2):597-608. doi: 10.1210/en.2017-00357.

PMID:
29126229
29.

Glucose uptake inhibition decreases expressions of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteocalcin in osteocytic MLO-Y4-A2 cells.

Takeno A, Kanazawa I, Notsu M, Tanaka KI, Sugimoto T.

Am J Physiol Endocrinol Metab. 2018 Feb 1;314(2):E115-E123. doi: 10.1152/ajpendo.00159.2017. Epub 2017 Oct 10.

30.

A case report of fulminant type 1 diabetes mellitus associated with drug-induced hypersensitivity syndrome in an elderly patient with coxsackie B4 virus infection and human leukocyte antigen-A24 haplotype.

Takeno A, Kanazawa I, Morita M, Takedani K, Miyake H, Yamamoto M, Nogami K, Kaneko S, Sugimoto T.

Endocr J. 2018 Jan 30;65(1):129-132. doi: 10.1507/endocrj.EJ17-0249. Epub 2017 Sep 29.

31.

Interaction between bone and glucose metabolism [Review].

Kanazawa I.

Endocr J. 2017 Nov 29;64(11):1043-1053. doi: 10.1507/endocrj.EJ17-0323. Epub 2017 Sep 30. Review.

32.

Association of Bone Mineral Density, Bone Turnover Markers, and Vertebral Fractures with All-Cause Mortality in Type 2 Diabetes Mellitus.

Miyake H, Kanazawa I, Sugimoto T.

Calcif Tissue Int. 2018 Jan;102(1):1-13. doi: 10.1007/s00223-017-0324-x. Epub 2017 Sep 30.

PMID:
28965188
33.

Early Mobilization after Pediatric Liver Transplantation.

Tsuboi N, Nozaki H, Ishida Y, Kanazawa I, Inamoto M, Hayashi K, Nishimura N, Nakagawa S, Kasahara M, Kamikubo T.

J Pediatr Intensive Care. 2017 Sep;6(3):199-205. doi: 10.1055/s-0036-1593387. Epub 2016 Sep 21.

34.

Association between the risk of falls and osteoporotic fractures in patients with type 2 diabetes mellitus.

Yokomoto-Umakoshi M, Kanazawa I, Kondo S, Sugimoto T.

Endocr J. 2017 Jul 28;64(7):727-734. doi: 10.1507/endocrj.EJ17-0011. Epub 2017 May 19.

35.

Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-β Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells.

Notsu M, Kanazawa I, Takeno A, Yokomoto-Umakoshi M, Tanaka KI, Yamaguchi T, Sugimoto T.

Calcif Tissue Int. 2017 Apr;100(4):402-411. doi: 10.1007/s00223-017-0243-x. Epub 2017 Feb 22.

PMID:
28229177
36.

Decreased Serum Insulin-like Growth Factor-I is a Risk Factor for Non-vertebral Fractures in Diabetic Postmenopausal Women.

Miyake H, Kanazawa I, Sugimoto T.

Intern Med. 2017;56(3):269-273. doi: 10.2169/internalmedicine.56.7416. Epub 2017 Feb 1.

37.

Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.

Kanazawa I, Tanaka KI, Notsu M, Tanaka S, Kiyohara N, Koike S, Yamane Y, Tada Y, Sasaki M, Yamauchi M, Sugimoto T.

Diabetes Res Clin Pract. 2017 Jan;123:9-17. doi: 10.1016/j.diabres.2016.11.010. Epub 2016 Nov 20.

PMID:
27914297
38.

Reduced muscle mass and accumulation of visceral fat are independently associated with increased arterial stiffness in postmenopausal women with type 2 diabetes mellitus.

Tanaka KI, Kanazawa I, Sugimoto T.

Diabetes Res Clin Pract. 2016 Dec;122:141-147. doi: 10.1016/j.diabres.2016.10.014. Epub 2016 Nov 2.

PMID:
27838345
39.

Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus.

Tanaka KI, Kanazawa I, Kaji H, Sugimoto T.

Bone. 2017 Feb;95:5-10. doi: 10.1016/j.bone.2016.11.007. Epub 2016 Nov 8.

PMID:
27836731
40.

Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis and Accumulation of Advanced Glycation End Products by Reducing Oxidative Stress in MC3T3-E1 Cells.

Kanazawa I, Tomita T, Miyazaki S, Ozawa E, Yamamoto LA, Sugimoto T.

Calcif Tissue Int. 2017 Mar;100(3):286-297. doi: 10.1007/s00223-016-0211-x. Epub 2016 Nov 10.

PMID:
27832315
41.

Fingolimod suppresses bone resorption in female patients with multiple sclerosis.

Miyazaki Y, Niino M, Kanazawa I, Suzuki M, Mizuno M, Hisahara S, Fukazawa T, Takahashi E, Amino I, Ochi R, Nakamura M, Akimoto S, Minami N, Fujiki N, Doi S, Shimohama S, Terayama Y, Kikuchi S.

J Neuroimmunol. 2016 Sep 15;298:24-31. doi: 10.1016/j.jneuroim.2016.06.007. Epub 2016 Jun 24.

PMID:
27609272
42.

[Diabetes mellitus and bone].

Kanazawa I, Sugimoto T.

Clin Calcium. 2016 Aug;26(8):1185-93. doi: CliCa160811851193. Japanese.

PMID:
27461503
43.

Decreased serum insulin-like growth factor-I level is associated with the increased mortality in type 2 diabetes mellitus.

Miyake H, Kanazawa I, Sugimoto T.

Endocr J. 2016 Sep 30;63(9):811-818. Epub 2016 Jun 25.

44.

Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus.

Tanaka S, Kanazawa I, Notsu M, Sugimoto T.

Diabetes Res Clin Pract. 2016 Jun;116:1-6. doi: 10.1016/j.diabres.2016.04.027. Epub 2016 Apr 23.

PMID:
27321309
45.

[Osteoporosis].

Kanazawa I, Sugimoto T.

Nihon Rinsho. 2016 Apr;74 Suppl 2:465-9. Japanese. No abstract available.

PMID:
27266136
46.

Long-term Efficacy and Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes Mellitus.

Tada Y, Kanazawa I, Notsu M, Tanaka K, Kiyohara N, Sasaki M, Sugimoto T.

Intern Med. 2016;55(10):1275-8. doi: 10.2169/internalmedicine.55.6011. Epub 2016 May 15.

47.

Molecular epidemiology and clinical spectrum of hereditary spastic paraplegia in the Japanese population based on comprehensive mutational analyses.

Ishiura H, Takahashi Y, Hayashi T, Saito K, Furuya H, Watanabe M, Murata M, Suzuki M, Sugiura A, Sawai S, Shibuya K, Ueda N, Ichikawa Y, Kanazawa I, Goto J, Tsuji S.

J Hum Genet. 2016 Apr;61(4):363-4. doi: 10.1038/jhg.2015.159. No abstract available.

PMID:
27108959
48.

Phylogenetics of family Enterobacteriaceae and proposal to reclassify Escherichia hermannii and Salmonella subterranea as Atlantibacter hermannii and Atlantibacter subterranea gen. nov., comb. nov.

Hata H, Natori T, Mizuno T, Kanazawa I, Eldesouky I, Hayashi M, Miyata M, Fukunaga H, Ohji S, Hosoyama A, Aono E, Yamazoe A, Tsuchikane K, Fujita N, Ezaki T.

Microbiol Immunol. 2016 May;60(5):303-11. doi: 10.1111/1348-0421.12374.

49.

[Bone and calcium metabolism in life-style related diseases].

Kanazawa I, Sugimoto T.

Clin Calcium. 2016 Mar;26(3):399-404. doi: CliCa1603399404. Review. Japanese.

PMID:
26923977
50.

Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 and 2.

Takeno A, Kanazawa I, Tanaka K, Notsu M, Yokomoto-Umakoshi M, Sugimoto T.

Endocr J. 2016 Apr 25;63(4):389-95. doi: 10.1507/endocrj.EJ15-0480. Epub 2016 Feb 3.

Supplemental Content

Loading ...
Support Center